✦ LIBER ✦

Phase 2 Study of TLK286 (GST P1-1 Activated Glutathione Analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer

Book ID: 117659441
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 265 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)80749-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of TLK286 (Glutathione An

Phase II Study of TLK286 (Glutathione Analog Activated by GST P1-1) in refractory colorectal cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Multi-institutional phase 2 study of TLK

Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

✍ J.J. KAVANAGH; D.M. GERSHENSON; H. CHOI; L. LEWIS; K. PATEL; G.L. BROWN; A. GARC 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

O-287 Phase 2 study of TLK286 (GST P1-1

O-287 Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory of resistant non-small cell lung cancer (NSCLC)

✍ Papadimitrakopoulou, Vassiliki; Blumenschein, George; Fossella, Frank; Figlin, R 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 376 KB

Phase 2 study of TLK286 (GST P1-1 activa

Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with non-small cell lung cancer who failed prior platinum-based regimens

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Phase 2 study of canfosfamide in combina

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

✍ John J Kavanagh; Charles F Levenback; Pedro T Ramirez; Judith L Wolf; Carla L Mo 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 404 KB

Phase 1b-2a study to reverse platinum re

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

✍ Siqing Fu; Wei Hu; Revathy Iyer; John J. Kavanagh; Robert L. Coleman; Charles F. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 298 KB 👁 1 views